randomized 2:1 to either LYR-210 (7500µg mometasone furoate) or sham control. The 24-week endpoints in the ENLIGHTEN trials assess LYR-210’s long-acting therapeutic effect as a bioresorbable ...

Based on these results, Prothena has made the decision to discontinue the development of birtamimab. Topline results were announced from a phase 3 trial evaluating birtamimab in patients with ...

Immunomodulatory properties have been identified in various antiparasitic agents and their potential therapeutic applications have been recognized. Antimalarials are valuable anti-inflammatory ...

Arterial flow-mediated dilation was significantly lower among marijuana smokers and THC-edible users than among nonusers. HealthDay News — Chronic cannabis smoking and tetrahydrocannabinol (THC ...

GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the disease, including Trelegy (fluticasone furoate, umeclidinium ...

Ozempic/Wegovy is the first drug on HHS's 2025 list of Medicare price negotiations. As the leaders of the pharmaceutical industry boarded their planes to come home from the JP Morgan Healthcare ...

Visit a quote page and your recently viewed tickers will be displayed here.

1 Department of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main St W, Hamilton, ON L8S 4L8, Canada 2 Department of Medicine, McMaster University, Hamilton, ON, Canada 3 ...